Specified drug-use survey in patients with systemic AL amyloidosis.

Specified drug-use survey in patients with systemic AL amyloidosis. - DRQ2L

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045330

Enrollment

120

Registered

2021-10-01

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic AL amyloidosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with systemic AL amyloidosis who were treated for the first time with the combination therapy of Darzquro Combination Subcutaneous Injection, cyclophosphamide hydrate, bortezomib, and dexamethasone (D-CyBorD therapy). Patients who understood the contents of this survey and gave consent to participate in this survey.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction)	—

Countries

Japan

Contacts

Public ContactHIROKAZU SHIRAI

Janssen Pharmaceutical K.K. Medical Affaires Delivery Unit

hshirai3@ITS.JNJ.com03-4411-5136

Outcome results